北京
分享至
劲方医药-B(02595.HK)发布公告，公司近期注意到若干报导，涉及 Revolution Medicines Inc.(“RevMed”)向第三方公司发出有关RAS抑制剂专利及商业秘密争议的函件。
本文源自：金融界AI电报
特别声明：以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布，本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
